CN Patent

CN117858883A — GalNAc单体和GalNAc寡核苷酸缀合物

Assigned to Lerner Biopharmaceutical Private Ltd · Expires 2024-04-09 · 2y expired

What this patent protects

GalNAc单体和使用所述GalNAc单体制备的GalNAc寡核苷酸缀合物，例如，携带GalNAc的核酸，例如可用于调节靶基因表达的sa‑RNAs和siRNAs。

USPTO Abstract

GalNAc单体和使用所述GalNAc单体制备的GalNAc寡核苷酸缀合物，例如，携带GalNAc的核酸，例如可用于调节靶基因表达的sa‑RNAs和siRNAs。

Drugs covered by this patent

inclisiran-sodium (INCLISIRAN SODIUM)

Patent Metadata

Patent number: CN117858883A
Jurisdiction: CN
Classification: —
Expires: 2024-04-09
Drug substance claim: No
Drug product claim: No
Assignee: Lerner Biopharmaceutical Private Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.